<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719914</url>
  </required_header>
  <id_info>
    <org_study_id>T101</org_study_id>
    <nct_id>NCT00719914</nct_id>
  </id_info>
  <brief_title>A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks</brief_title>
  <acronym>IC TITAN</acronym>
  <official_title>IntraCoronary Treatment With Integrilin To Improve ANgiographic Outcomes (IC TITAN - TIMI 47) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this research study is to try to improve the results of the standard
      treatment for heart attacks. Normally, heart attack patients get a fast dose and a slow dose
      of eptifibatide in the emergency room, shortly after arriving. This drug is usually given
      through a vein in the arm. However, eptifibatide can also be injected directly into the
      heart's blood supply just before angioplasty, a common procedure to unblock a blood vessel in
      the heart. This new way of giving the drug is being studying.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the IC-TITAN study is to demonstrate that an IC bolus of
      eptifibatide added to an upstream double-bolus and infusion regimen of eptifibatide
      administered intravenously and initiated early in the ER will result in significant
      additional clot resolution in vivo when compared with an IC injection of placebo (saline).
      The primary endpoint chosen to evaluate this hypothesis is the improvement in percent
      diameter stenosis of the culprit artery following the IC bolus administration of eptifibatide
      vs. IC placebo (saline) as assessed with quantitative coronary angiography (QCA).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Percent Diameter Stenosis of the Culprit Artery Following the IC Bolus Administration of Eptifibatide vs. IC Placebo (Saline) as Assessed With Quantitative Coronary Angiography (QCA)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>ST-Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intracoronary injection of eptifibatide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intra-coronary injection of normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eptifibatide</intervention_name>
    <description>Intra-coronary injection, weight based, of eptifibatide.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eptifibatide</intervention_name>
    <description>Intra-coronary injection, based on weight, of eptifibatide</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Intra-coronary injection, weight based, of normal saline.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical

          -  Patients (men or women) at least 18 years of age and

          -  Presenting with ischemic chest discomfort &gt;20 minutes and &lt;6 hours of duration
             suggestive of acute myocardial infarction

        AND:

        ECG

          -  ST elevation &gt;1mm (&gt;0.1mV) in two contiguous limb leads OR &gt;2mm (&gt;0.2mV) in two
             contiguous precordial leads

        Exclusion Criteria:

        CLINICAL

          -  Maximal systolic blood pressure &lt;80 mmHg AFTER initial fluid and/or pressor
             resuscitation

          -  Uncontrolled hypertension (SBP&gt;180 OR DBP &gt;110) at time of enrollment

          -  Ventricular fibrillation or ventricular tachycardia requiring DC cardioversion

          -  Sinus bradycardia (HR &lt;50/min), third degree or advanced second degree heart block.

          -  Known pregnancy

          -  New or suspected new left bundle branch block

        BIOCHEMICAL

          -  Known thrombocytopenia (platelet count &lt;100,000)

          -  Known severe renal insufficiency (creatinine &gt;4.0 mg/dL)

        INCREASED BLEEDING RISK

          -  Active or recent (&lt;1 year) bleeding or gastrointestinal hemorrhage

          -  Major surgery &lt;1 month

          -  Known coagulopathy, platelet disorder or history of thrombocytopenia: If a patient is
             known to be on chronic warfarin therapy, the International Normalized Ratio (INR) must
             be known to be &lt;1.6 in order for the patient to be included

          -  Known neoplasm

          -  Any history of hemorrhagic cerebrovascular disorder or active intracranial pathology

        MEDICATIONS

          -  Administration of a fibrinolytic agent within 7 days

          -  Known allergy or contraindication to eptifibatide OR aspirin OR heparin

          -  Treatment with another GP IIb/IIIa inhibitor within 7 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Braunwald, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>TIMI Study Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. Michael Gibson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>TIMI Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Research Associates</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crittenton Hospital Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Ohio Heart Clinic</name>
      <address>
        <city>Mansfield</city>
        <state>Ohio</state>
        <zip>44906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>July 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <results_first_submitted>July 24, 2012</results_first_submitted>
  <results_first_submitted_qc>July 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2012</results_first_posted>
  <last_update_submitted>July 24, 2012</last_update_submitted>
  <last_update_submitted_qc>July 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>C. Michael Gibson, MS, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>eptifibatide</keyword>
  <keyword>Integrilin</keyword>
  <keyword>ST-Elevation Myocardial Infarction</keyword>
  <keyword>Acute Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eptifibatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Additional Bolus of Eptifibatide</title>
          <description>Intracoronary injection of eptifibatide</description>
        </group>
        <group group_id="P2">
          <title>Bolus of Normal Saline</title>
          <description>Intracoronary injection of normal saline.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Additional Bolus of Eptifibatide</title>
          <description>Intracoronary injection of eptifibatide</description>
        </group>
        <group group_id="B2">
          <title>Bolus of Normal Saline</title>
          <description>Intra-coronary injection of normal saline.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="10.2"/>
                    <measurement group_id="B2" value="67" spread="9.5"/>
                    <measurement group_id="B3" value="61.6" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Percent Diameter Stenosis of the Culprit Artery Following the IC Bolus Administration of Eptifibatide vs. IC Placebo (Saline) as Assessed With Quantitative Coronary Angiography (QCA)</title>
        <time_frame>30 days</time_frame>
        <population>study terminated due to low enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>Additional Bolus of Eptifibatide</title>
            <description>Intracoronary injection of eptifibatide</description>
          </group>
          <group group_id="O2">
            <title>Bolus of Normal Saline</title>
            <description>Intra-coronary injection of normal saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Percent Diameter Stenosis of the Culprit Artery Following the IC Bolus Administration of Eptifibatide vs. IC Placebo (Saline) as Assessed With Quantitative Coronary Angiography (QCA)</title>
          <population>study terminated due to low enrollment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Additional Bolus of Eptifibatide</title>
          <description>Intracoronary injection of eptifibatide</description>
        </group>
        <group group_id="E2">
          <title>Bolus of Normal Saline</title>
          <description>Intra-coronary injection of normal saline.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to poor enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>C. Michael Gibson, MS, MD</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-632-7753</phone>
      <email>mgibson@perfuse.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

